Search results
Results from the WOW.Com Content Network
The first outbreak involving colistin-resistant, carbapenem-resistant K. pneumoniae (CRKP) in the U.S. was discovered in Detroit, Michigan in 2009, involving three different healthcare institutions. [55] In an active surveillance study in seven U.S. states over two years, the crude overall incidence of CRE was 2.93 per 100,000 population.
PZ-601 is a carbapenem antibiotic currently being tested as having a broad spectrum of activity including strains resistant to other carbapenems. Despite early Phase II promise, Novartis (who acquired PZ-601 in a merger deal with Protez Pharmaceuticals) recently dropped PZ-601, citing a high rate of adverse events in testing.
The concern is that carbapenem is often used as a drug of last resort when battling resistant bacterial strains. New slight mutations could result in infections for which healthcare professionals can do very little, if anything, to treat patients with resistant organisms. A number of mechanisms cause carbapenem resistance in the Enterobacteriaceae.
Treatment with an aminoglycoside or carbapenem is usually indicated. Carbapenems are a class of beta-lactam antibiotics with a broad spectrum of antibacterial activity. They have a structure that renders them highly resistant to beta-lactamases. Examples of carbapenems include meropenem and imipenem.
The infection was identified as a carbapenem-resistant Klebsiella pneumoniae strain bearing the novel gene bla NDM-1. The authors concluded that the new resistance mechanism "clearly arose in India, but there are few data arising from India to suggest how widespread it is". [15]
The evolution of bacteria on a "Mega-Plate" petri dish A list of antibiotic resistant bacteria is provided below. These bacteria have shown antibiotic resistance (or antimicrobial resistance). Gram positive Clostridioides difficile Clostridioides difficile is a nosocomial pathogen that causes diarrheal disease worldwide. Diarrhea caused by C. difficile can be life-threatening. Infections are ...
The primary measure of efficacy was mortality from all causes within 28 days of treatment in participants with a confirmed infection with carbapenem-resistant A. baumannii. [2] Of those who received sulbactam/durlobactam, 19% (12 of 63 participants) died, compared to 32% (20 of 62 participants) who received colistin; this demonstrated that ...
Antibiotic combinations are increasingly important because of antimicrobial resistance. [2] This means that individual antibiotics that used to be effective are no longer effective, [ 1 ] and because of the absence of new classes of antibiotic, they allow old antibiotics to be continue to be used. [ 2 ]